Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7062 | PPT |
| Potent, subtype-selective estrogen receptor agonist (EC50 ~ 200 pM); displays 410-fold selectivity for ERα over ERβ. Prevents ovariectomy-induced weight gain and loss of bone mineral density, and induces gene expression in the hypothalamus following systemic administration in vivo. | |
| BCC7065 | SQ 22536 |
| Inhibitor of adenylyl cyclase (IC50 = 1.4 μM). Inhibits PGE1-stimulated increases in cAMP levels in intact human platelets. | |
| BCC7069 | N-Arachidonylglycine |
| Endogenous anandamide-like compound. Lacks affinity for CB1 receptors (Ki > 10 μM), VR1 receptors (EC50 > 10 μM) and anandamide transporters (IC50 > 50 μM) but causes hot-plate analgesia in mice when given orally, and suppresses tonic inflammatory pain. Also endogenous GlyT2 inhibitor. | |
| BCC7070 | O-2093 |
| Inhibitor of anandamide uptake (IC50 = 17.3 μM) with little or no activity at CB1, CB2, TRPV1 and FAAH. Intravenous administration inhibits limb spasticity in mice with chronic relapsing experimental allergic encephalomyelitis (CREAE). | |
| BCC7072 | GYKI 52466 dihydrochloride |
| Selective non-competitive AMPA receptor antagonist (IC50 values are 10-20, ~ 450 and >> 50 μM for AMPA- , kainate- and NMDA-induced responses respectively). Skeletal muscle relaxant and orally-active anticonvulsant. Has anti-proliferative effects in transformed cells. Also available as part of the AMPA Receptor. Also available as part of the Kainate Receptor. | |
| BCC7073 | SU 4312 |
| Potent and selective inhibitor of VEGFR and PDGFR tyrosine kinases (IC50 values are 0.8 and 19.4 μM respectively). Selective over EGFR and c-Src tyrosine kinases. | |
| BCC7077 | PPAHV |
| Non-pungent vanilloid TRPV1 (VR1) receptor agonist (Ki = 3.1 μM) that displays non-cooperative binding. Induces apoptosis via a non-VR1 mechanism in Jurkat cells and causes vasoconstriction in vivo. | |
| BCC7080 | (-)-[3R,4S]-Chromanol 293B |
| Enantiomer that selectively inhibits the slow component of delayed rectifier K+ current (IKs). Block is use-dependent and 7-fold more potent than the (+)-(3S,4R) enantiomer (IC50 values are 1.36 and 9.6 μM respectively). Has negligible inhibitory action at KV11.1 (hERG) channels (IC50 > 30 μM). Racemate Chromanol 293B also available. | |
